SAGILITY · NSE
SAGILITY LIMITED
₹45.25
+0.87% (+₹0.39)
Prev. close
₹44.86
Volume
4,22,05,390
Delivery %
50.6%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
6 analyst stances · last 90 days · one per analyst
Trackable
5 · 5 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
1 · 1 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Sagility, advising a buy at ₹45.25 with a target of ₹50 and a stop‑loss at ₹42.80, citing the stock's attract…” | Sumeet BagadiaChoice Equity Broking | Sagility | PENDING | |
| “Bullish on Sagility, recommending a buy at ₹44 with a stop loss at ₹42 and a target of ₹48. The stock formed a bullish p…” | Sachin GuptaChoice Equity Broking | Sagility | PENDING | |
| “Bullish on Sagility for a two-to-three-week timeframe, recommending a buy at ₹45.60 with a target price of ₹49.50 and a …” | Nagaraj ShettiHDFC Securities | Sagility | MISS | |
| “Bullish on Sagility, recommending a buy at ₹44 with a target of ₹48 and a stop loss at ₹42.” | Sumeet BagadiaChoice Equity Broking | Sagility | PENDING | |
| “Bullish on Sagility, recommending a buy at ₹43.17 with a target of ₹46.50 and a stop loss at ₹41.50.” | Sumeet BagadiaChoice Equity Broking | Sagility | PENDING | |
| “Initiated coverage on Sagility with a Buy rating and a 12-month target price of ₹55, implying around 20% upside. The bro…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Sagility | PENDING | |
| “Bullish on Sagility for the short term, recommending a buy at ₹46.50 with a target of ₹54, and a stop loss at ₹42.” | Mehul KothariAnand Rathi | Sagility | MISS | |
| “Bullish on Sagility for the next six months, recommending a buy between ₹43 and ₹44 with a target of ₹54 and a stop loss…” | Pabitro MukherjeeBajaj Broking | Sagility | PENDING | |
| “Bullish on Sagility, recommending a buy at ₹52.63 with a target price of ₹56.5 and a stop loss at ₹50.5. This call is fo…” | Sumeet BagadiaChoice Equity Broking | Sagility | MISS | |
| “Bullish on Sagility, recommending a buy at ₹53.28 with a target price of ₹57 and a stop loss at ₹51.4. This call is for …” | Sumeet BagadiaChoice Equity Broking | Sagility | MISS | |
| “Recommends buying Sagility for the short-term, targeting ₹59 with a stop-loss at ₹49.6. The stock broke out from multi-w…” | Vinay RajaniHDFC Securities | Sagility | MISS | |
| “Recommends buying Sagility at ₹76 with a target price of ₹82 and a stop loss at ₹73.5. This call was made on Monday, Oct…” | Sumeet BagadiaChoice Equity Broking | Sagility | NOT TRIGGERED | |
| “Recommends buying Sagility at ₹46.37 with a target price of ₹50 and a stop loss at ₹44.9, for Monday, October 13.” | Sumeet BagadiaChoice Equity Broking | Sagility Ltd | MISS | |
| “Recommends buying Sagility at ₹46, targeting ₹52, with a stop loss at ₹44 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Sagility | MISS |
Market commentary · 3 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Sagility, seeing more than 50% rerating potential in a best-case scenario. The company's current valuation re…” | Jefferies AnalysisJefferies | Sagility | — | |
| “Sagility offers the best risk-reward among mid-sized IT peers, with a 50%-plus re-rating potential in the best-case scen…” | Jefferies AnalysisJefferies | Sagility | — | |
| “Bullish on Sagility, anticipating a 20% upside over the next 6 to 12 months. The optimism stems from the company's stron…” | Sunny AgrawalSBI Cap Securities | Sagility | — |
Fundamentals
About SAGILITY LIMITED
Sagility Limited engages in the rendering voice and non-voice business process management and back-office transaction processing services in India, Jamaica, the Philippines, the United States, and Colombia. The company offers claims and membership managed services, such as digital mailroom, product and plan configuration, enrollment and billing, adjudication and adjustment, and appeals management solutions; engagement services; and payer clincal services. It also provides network operations suite comprising provider credentialing, provider data management, provider accuracy, and provider forward solutions; healthcare consulting services; sagility synchrony; healthcare payment integrity services; and provider services that includes patient access, clinical denials management, revenue cycle management, patient engagement, and coding solutions. In addition, the company offers member lifecycle management, provider lifecycle management, claims management, clinical utilization and care management, payment integrity, and provider revenue cycle management solutions. The company was formerly known as Sagility India Limited and changed its name to Sagility Limited in August 2025. Sagility Limited was incorporated in 2021 and is based in Bengaluru, India. The company operates as a subsidiary of Sagility B.V.
Details
Sector
Healthcare
Industry
Health Information Services
CEO
Mr. Ramesh Gopalan
Headquarters
Bengaluru
Employees
51,486
Website
sagility.comExchange
View on NSE ↗Key stats
Market cap
₹20,405.91 Cr
P/E ratio (TTM)
19.8
Dividend yield
0.71%
EPS (TTM)
₹2.20
Beta (1Y · daily vs NIFTY 50)
0.92
Shares float
228.53 Cr
EPS · quarter ended Sept 2026
₹0.61
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹4,218.41 Cr | ₹4,753.56 Cr | ₹5,569.92 Cr | ₹7,192.85 Cr | |
EBITDA | ₹1,044.86 Cr | ₹1,116.04 Cr | ₹1,354.19 Cr | ₹1,825.43 Cr |
| ₹143.57 Cr | ₹228.27 Cr | ₹539.12 Cr | ₹924.77 Cr | |
Diluted EPS | ₹0.31 | ₹0.49 | ₹1.17 | ₹1.98 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2025 could not be checked against the company's own annual report: this page shows ₹539.12 Cr while the annual report gives ₹271.48 Cr (49.6% apart).
EBITDA for Mar 2025 could not be checked against the company's own annual report: this page shows ₹1,354.19 Cr while the annual report gives ₹562.40 Cr (58.5% apart).
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹10,590.48 Cr | ₹10,664.20 Cr | ₹11,050.66 Cr | ₹12,601.08 Cr | |
| ₹2,871.60 Cr | ₹2,531.71 Cr | ₹1,401.94 Cr | ₹1,110.54 Cr | |
Stockholders' equity | ₹6,206.67 Cr | ₹6,443.13 Cr | ₹8,336.05 Cr | ₹9,659.10 Cr |
CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2025-03-31, 2026-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2025-03-31, 2026-03-31, 2023-03-31, 2024-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2023-03-31, 2024-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹856.78 Cr | ₹973.26 Cr | ₹1,214.07 Cr | ₹1,202.97 Cr | |
Investing cash flow | ₹-129.06 Cr | ₹-469.06 Cr | ₹-964.21 Cr | ₹-710.69 Cr |
| ₹-544.62 Cr | ₹-751.34 Cr | ₹-256.07 Cr | ₹-501.40 Cr | |
Capital expenditure | ₹-143.68 Cr | ₹-182.73 Cr | ₹-124.44 Cr | ₹-192.21 Cr |
End cash position | ₹585.29 Cr | ₹344.13 Cr | ₹343.76 Cr | ₹357.92 Cr |
Debt issued, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 24–Mar 25(3Q) | Jun 25–Sep 25(2Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|
| Promoter | 82.39% | 67.38% | 50.95% |
| Public | 17.61% | 32.62% | 49.05% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| SAGILITY LIMITED | ₹19,820.75 Cr | ₹42.34 | 19.2 | 2.05 | 9.6% | 0.11 | +29.1% | -19.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.